1. Introduction {#sec1}
===============

Status epilepticus (SE) is a fatal neurological disorder with a high mortality rate. This condition often occurs as a ramification of stroke ([@bib127]; [@bib114]), traumatic brain injury ([@bib38]; [@bib3]), infection ([@bib154]; [@bib79]), metabolic disorder ([@bib131]; [@bib86]), or alcohol or drug withdrawal ([@bib77]; [@bib28]) and is observed in patients with a history of epilepsy ([@bib145]). SE was previously defined as either a seizure that lasts ≥30 min or two or more consecutive seizures with the absence of complete conscious recovery between them ([@bib102]). However, generalised tonic-clonic seizures only last a maximum of 3 min, thus if a seizure surpasses this duration, it becomes self-sustaining ([@bib162]). In a typical clinical setting, 30 min is a long time to wait to assist someone experiencing continuous seizures because a larger scale of neurological damage will occur, resulting in self-sustaining refractory seizures, thus making the use of anti-epileptic drugs (AEDs) futile ([@bib30]). As the duration of SE increases, the effectiveness of AEDs gradually decreases, often with a total decline in drug efficacy ([@bib93]; [@bib159]) that results in increased comorbidities and poor quality of life. Therefore, the window for diagnosis is further reduced; the current definition of SE according to the International League Against Epilepsy (ILAE) is a persistent seizure that lasts for ≥5 min, with long-term detrimental consequences such as neurodegeneration and formation of aberrant neural networks if the seizure activity exceeds 30 min ([@bib146]).

2. The animal models of SE {#sec2}
==========================

The 30-minute time period is still applicable in experimental animal models, as this is the time required for the models to develop SE ([@bib94]). There is a dire need for a new range of AEDs in patients who exhibit pharmacoresistance, highlighting the necessity of animal models. A good animal model ensures a smooth transition from preclinical testing to human clinical trials, thus establishing a better understanding of the underlying pathophysiology and mechanisms of SE. Animal models also allow good comprehension of the pharmacokinetics, side effects, potency, efficacy, and tolerance of the potential therapeutic agents being tested. Therefore, a successful model must mimic the observed symptoms of SE in humans, such as convulsions (lasting more than 5 min), memory loss, muscle spasms, falling, and confusion. As observed in clinical cases, a "latency period" must occur after the initial injury, which should then be followed by the occurrence of spontaneous recurrent seizures (SRS) ([@bib24]; [@bib84]). The model must also be able to replicate the neuropathological injuries observed in the brain regions of SE patients; the 30-minute period is crucial for this development ([@bib45]; [@bib152]). Finally, the model must simulate the development of pharmacoresistance to certain anticonvulsants (observed in refractory SE) and allow testing of potential new drugs ([@bib70]; [@bib95]; [@bib67]; [@bib27]). Before creating such an animal model, the investigator must first take the following factors into account: time and effort required to create the model, costs, laboratory skills of the researchers, availability of materials/research environment, strain/susceptibility of animals to seizures, pharmacokinetics, and the mortality rate of animals. The kindling model, for example, is a well-known seizure model created by repeated electrical stimulation via implanted depth electrodes ([@bib137]). Although this technique is effective, it is also costly, laborious, and time consuming ([@bib88]; [@bib137]) making the use of chemoconvulsants a more convenient method. The frequency of SRS is also lower ([@bib18]) than that of chemoconvulsant models. This technique requires precision and skills on the researcher\'s part as there is a risk of damaging the implanted electrodes, rendering them unreliable for chronic experiments ([@bib137]). Other electrical stimulation models such as the perforant path approach produce less neurodegeneration than chemoconvulsant models such as kainic acid and pilocarpine models ([@bib123]), thus making them a less desirable option. Chemoconvulsants such as pilocarpine and kainic acid are much easier to use and do not require sophisticated setups. However, compared with pilocarpine, seizures resulting from intracerebral kainic acid injections are more severe ([@bib73]); the stages of seizure are also difficult to distinguish because their progression is very rapid ([@bib84]), unlike the stages induced by pilocarpine, which can be easily distinguished using the Racine scale ([@bib121]). Kainic acid-induced animals also show a higher degree of anxiety ([@bib122]) and depression-like behaviour ([@bib52]). Compared with pilocarpine, it is more difficult to induce SE in mice with systemic administration of kainic acid ([@bib96]). Studies in mouse models have shown that the C57BL/6, C57BL/10, and F1 C57BL/6∗CBA/J strains are resistant to systemic administration of kainic acid, while the FVB/N, ICR, and DBA/2 J strains are vulnerable ([@bib97]). Kainic acid models have also proven to be impractical for pharmacoresistance studies because of differences in AED reactions ([@bib123]). Another limitation is the excitotoxic effect of kainic acid, which makes separating direct neuronal damage from seizure-induced neuronal damage difficult ([@bib123]). As found by Rao and colleagues, while creating a kainic acid model of SE, 77% of their animals developed moderate bilateral neurodegeneration in various hippocampal regions, whereas 23% developed massive neurodegeneration in all regions of the hippocampus ([@bib120]). This was observed even though the kainic acid dosage used, and the frequency of SRS recorded were the same for both groups. Kainic acid is also more expensive to purchase than its competitor, pilocarpine ([@bib84]). Unlike kainic acid, pilocarpine can replicate the kindling stages of SE development ([@bib116]), making it a more efficient chemoconvulsant. Studies have also reported differences in SRS frequency between kainic acid and pilocarpine models. Although kainic acid can induce SRS in animal models, these seizures eventually decline within 22--46 days, making this model undesirable ([@bib26]; [@bib33]). However, studies have also shown that pilocarpine-induced SRS occur at a constant frequency for an extended length of time (120 days - [@bib25]; 325 days -- [@bib101]). This period has been reported as the "entire observation period", meaning that if researchers were to extend their observation period, the pilocarpine model would most likely exceed the stated time period, clearly making it a stable model. The pilocarpine model also mimics the "latency period" after the initial insult ([@bib149]; [@bib84]). Studies have found similar electrophysiological and morphological abnormalities in the rat hippocampus of the pilocarpine model of SE ([@bib66]; [@bib100]) and human SE ([@bib129]; [@bib6]; [@bib92]; [@bib65]). The pilocarpine model is also capable of replicating several other characteristics such as dentate granule cell dispersion as well as supragranular and intragranular mossy fibre sprouting ([@bib101]), which is commonly observed in clinical cases ([@bib61]; [@bib7]). Thus, although several seizure models have been proposed, ranging from the use of chemoconvulsants to electrical stimulation, the pilocarpine model is one of the oldest and most well-studied animal models of SE.

3. The pilocarpine model: the early days {#sec3}
========================================

First described in the early 1980s, the pilocarpine model is characterised by a single large dose of pilocarpine; the dose lies in the range of 300--400 mg/kg for rats ([@bib147]). The preferred method of administering the drug is usually via intraperitoneal (i.p.) or intrahippocampal injections; both methods elicit identical electrographic and behavioural effects, as well as similar histopathological alterations ([@bib46]). Intrahippocampal injections, however, have a higher survival rate (71%) than i.p. injections ([@bib46]). Upon pilocarpine administration, the animals are usually stationary for 10 min, followed by facial twitching (Stage I); head nodding (Stage II); forelimb clonus (Stage III); bilateral forelimb clonus and rearing (Stage IV); and bilateral forelimb clonus with rearing and falling (Stage V) ([@bib121]). The Racine scale is often used to grade seizure severity; Stage V and above indicate severe brain damage and development of SE ([@bib121]). After 30 min, these seizures become self-sustaining and occur at 15-minute intervals, persisting for hours until a suitable AED is used to stop the seizures ([@bib34]). SE induced via chemoconvulsants are shown to be more difficult to terminate as compared to electrically induced models ([@bib9]). Thus, several studies utilize a repetitive dose or a combination of AEDs to terminate SE and reduce mortality rates. Pilocarpine is an M1 muscarinic acetylcholine receptor agonist that promotes continuous excitatory activity, resulting in brain tissue damage ([@bib80]). M1 receptor knockout mice show no signs of seizures when administered pilocarpine, and M1 is the only muscarinic receptor subtype that can mediate seizure activity ([@bib55]; [@bib22]). In addition, when atropine, a competitive antagonist of the muscarinic acetylcholine receptor, is applied to rats prior to pilocarpine treatment, there is an absence of seizure initiation, which is significant for large (150 mg/kg) and small doses (1 mg/kg) of atropine ([@bib60]; [@bib69]; [@bib16]). Atropine administration to pilocarpine-treated rats immediately upon forelimb clonus results in termination of seizures, whereas those administered atropine 20 min after forelimb clonus do not indicate any decline in seizure activity, proceeding to SE and eventually death ([@bib69]; [@bib16]). This finding clearly shows that muscarinic receptors are responsible for the onset of seizure activity in the pilocarpine model of SE, and as observed in clinical cases, anticholinergics are inefficient anticonvulsants for SE. Furthermore, when pilocarpine pre-treated rats are given hemicholinium-3, an acetylcholine synthesis inhibitor, progression of SE is blocked ([@bib69]). This occurs because hemicholinium-3 prevents the re-uptake of choline by high-affinity choline transporters at the presynaptic membrane, causing an 80% reduction in the normal acetylcholine concentration ([@bib42]). This indirectly reduces the efficiency of the M1 muscarinic acetylcholine receptors on the postsynaptic membrane ([@bib31]), highlighting the importance of presynaptic cholinergic activity in the pilocarpine model of SE. Similarly, studies have shown that seizure activity in pilocarpine models can be blocked by a 15-minute pre-treatment with diazepam (a common AED), and initial tonic-clonic seizures can also be terminated via diazepam administration, making this a suitable model for SE ([@bib69]). Seizures induced by pilocarpine begin in the ventral forebrain; the nucleus accumbens is most likely the primary site of injury because of the presence of a high density of muscarinic receptors ([@bib74]; [@bib112]). The neocortex suffers the most significant injuries, characterised by swollen dendrites and cell bodies and pruning of axons ([@bib32]). Animals often suffer a 10%--20% reduction in body weight post-SE, with eventual recovery to baseline values after 1 week ([@bib149]). Mortality rates in this model are very high, with some studies reporting 30%--40% mortality in male Wistar rats treated with a pilocarpine dose of 300--400 mg/kg ([@bib147], [@bib149]; [@bib87]) and other studies reporting 40%--55% mortality with a dose of 320--360 mg/kg ([@bib40]; [@bib50]). A notable observation is the differences in rat strains; Sprague-Dawley rats appear to have lower mortality rates (5%) than Wistar rats (30%) when treated with the same dose of pilocarpine, 380 mg/kg ([@bib81]; [@bib117]). However, the mortality rate is still a problem, as it is not standardised even within the same rat strain. Thus, using Sprague-Dawley rats does not always ensure a reduction in the number of deaths. For instance, when Sprague-Dawley rats are treated with 400 mg/kg of pilocarpine, SE is generated in 83% of animals, but the mortality rate is 100% ([@bib69]). Another observation in this study is that SE is not induced in all rats. Therefore, when using pilocarpine alone, a higher dose is required to increase the likelihood of replicating the entire disease as well as reducing the latency to SE, which further increases the mortality rate ([@bib32]; [@bib87]). Studies have also tried to induce SE by splitting the single large dosage of pilocarpine into several smaller doses ([@bib49]). This however was not fruitful in all animal models. For example, studies have administered single injections of 100 mg/kg of pilocarpine intraperitoneally to induce SE in mice, with the total dosage reaching up to 800 mg/kg ([@bib111]). Even with such a high overall dose, only 54% of the animals survived the procedure and developed SE. Using such a high dosage of pilocarpine results in an unnecessary wastage of the drug. There is also a limit to the concentration of pilocarpine that can be administered to animals; a higher concentration of pilocarpine results in a higher toxicity level ([@bib116]). To combat this issue, studies have suggested the use of lithium as a pre-treatment before pilocarpine administration ([@bib60]; [@bib153]).

4. A new hope: the lithium-pilocarpine model of SE {#sec4}
==================================================

The lithium-pilocarpine model of SE is generally characterised by administration of lithium chloride (LiCl; 127 mg/kg), followed by pilocarpine administration (30 mg/kg) 18 h later ([@bib41]). Methylscopolamine (1 mg/kg in rats) is also given to the animals 30 min before pilocarpine administration to reduce any peripheral effects caused by pilocarpine, which unlike scopolamine, does not cross the blood brain barrier (BBB) ([@bib36]). Absence of methylscopolamine results in animals displaying symptoms of peripheral cholinergic activity such as tremor, salivation, piloerection, chromodacryorrhoea, and diarrhoea after pilocarpine administration ([@bib32]; [@bib153]). However, higher doses of methylscopolamine (≥20 mg/kg in rats) can block seizure activity ([@bib147], [@bib148]). Lithium, used previously for psychiatric chemotherapy and bipolar disorder ([@bib39]), potentiates the effect of pilocarpine by indirectly activating T-lymphocytes and mononuclear cells, which in turn results in higher serum IL-1β levels, thus altering the BBB permeability and increasing pilocarpine uptake ([@bib90]). Researchers have also found variation in muscarinic receptor binding in the presence of lithium ([@bib62]; [@bib48]). Pre-treatment with LiCl has been reported to increase acetylcholine release, with some studies observing a six-fold increase in the hippocampus ([@bib54]; [@bib68]; [@bib58]). This results in more acetylcholine crossing the synaptic cleft and reaching the postsynaptic membrane where it activates M1 muscarinic receptors. LiCl is suggested to play a role in phosphoinositide metabolism, with lithium pre-treatment resulting in a 40-fold increase in myo-inositol-1-phosphate compared with the mere 4-fold increase with pilocarpine alone ([@bib2]; [@bib60]; [@bib132]; [@bib32]). Myo-inositol-1,4,5-trisphosphate (IP~3~), an inositol phosphate derived from phosphoinositide hydrolysis, has also been associated with increased seizure activity ([@bib99]; [@bib51]). IP~3~ is a second messenger molecule, which upon binding to IP~3~ receptors (Ca^2+^ channels), induces Ca^2+^ release from the endoplasmic reticulum (ER) to the cytoplasm, which in turn causes store-operated Ca^2+^ entry in an attempt to refill the depleted ER stores ([@bib72]). This further increases the concentration of intracellular Ca^2+^, resulting in enhanced vesicular transport and acetylcholine release at the presynaptic membrane ([@bib23]), which then enhances the activation of muscarinic receptors on the postsynaptic membrane. The increased Ca^2+^ levels are also accompanied by cellular damage and oxidative stress, which increase extracellular lactate, choline, and glycerol; the use of a Ca^2+^ channel blocker reduces SE-induced membrane damage ([@bib64]). Animals pre-treated with LiCl show an increased sensitivity to pilocarpine, with a 20-fold shift in the dose-response curve for seizure generation ([@bib32]). Thus, the use of LiCl allows for a substantial reduction in the pilocarpine dose required, along with a reduction in the time to SE onset. Both the LiCl-pilocarpine and high-dose pilocarpine models follow the same pattern in seizure initiation and propagation ([@bib32]; [@bib106]). Both models also generate identical behavioural, electrographic, metabolic, and neuropathological symptoms ([@bib32]; [@bib106]). The LiCl-pilocarpine model has a higher SE induction rate than pilocarpine alone, with some investigators even reporting 100% SE induction compared with pilocarpine, which only results in 60% SE induction ([@bib50]; [@bib1]), although the numbers may vary among laboratories. The LiCl-pilocarpine model has a lower mortality rate and has been shown to generate more consistent and prolonged seizures with reproducible results, thus making it a promising model for studying SE.

5. The limitations strike back: imperfections in the lithium-pilocarpine model {#sec5}
==============================================================================

Unfortunately, the lower mortality rate is not negligible because it ranges between 92% and 95% ([@bib69]; [@bib105]; [@bib63]). Decreasing the pilocarpine dose in the lithium-pilocarpine model reduces the mortality rate, but this is also accompanied with a decline in SE induction ([@bib69]; [@bib63]). Another factor to consider is the reports of alterations in SE induction and mortality rates among different rodent strains ([@bib29]; [@bib160], [@bib161]). Researchers have observed variations in SE induction and pilocarpine sensitivity between different batches of the same strain of rats (Sprague-Dawley) purchased from different breeders ([@bib10]). These groups indicate strong substrain differences between each other that most likely result in the wide-ranging experimental data reported from different laboratories. These differences between strains and substrains have also been noted in mice ([@bib17]; [@bib107]; [@bib128]; [@bib11]). Another study also found remarkable intrastrain differences in seizure predisposition between Wistar rats from two different breeding locations as well as rats purchased at different times from the same breeding location ([@bib118]). Therefore, these genetic differences can have a major impact on the development of SE models, causing difficulty in reproducing results even within the same facility. One possibility for the observed pilocarpine resistance is the presence of the multidrug transporter P-glycoprotein (PGP), which is a transporter that removes pilocarpine from the BBB, serving a protective role. Studies have shown that PGP knockout mice require a lower dose of pilocarpine for SE induction than their wild-type counterparts ([@bib124]). Studies have revealed that PGP knockout mice injected with a low dose of pilocarpine do not show any increase in brain uptake of the drug, but those injected with a higher dose show significantly increased brain uptake ([@bib125]; [@bib151]; [@bib85]). In addition, pre-treatment of wild-type mice with the PGP inhibitor tariquidar causes an increase in pilocarpine brain uptake similar to that observed in PGP knockout mice, thus emphasizing that pilocarpine is carried by the PGP multidrug transporter ([@bib12]). Female wild-type mice reportedly require a higher pilocarpine dose for SE induction than males ([@bib124]). The absence of this phenomenon in PGP knockout mice could therefore be explained by a PGP-dependent mechanism ([@bib124]). Verapamil, a common PGP substrate, showed lower brain uptake in female mice than male mice, suggesting higher PGP expression levels in female mice ([@bib35]). Because PGP expression levels are influenced by sexual hormone levels occurring during the oestrus cycle ([@bib130]), several studies have reported similar sex-related differences in SE development in both rats and mice ([@bib98]; [@bib104]; [@bib21]). Several studies have implicated the excitatory neurotransmitter glutamate in the underlying mechanism that activates PGP ([@bib14]; [@bib167]; [@bib56]; [@bib136]). As mentioned earlier, animals that reach Stage V on the Racine scale develop SE and no longer show any response to atropine treatment, suggesting activation of other downstream pathways, in addition to cholinergic cells, resulting in SE ([@bib69]; [@bib16]). Cultured hippocampal neuron studies have revealed that pilocarpine-induced M1 receptor activation results in an imbalance between excitatory and inhibitory signals, which in turn results in the development of SE ([@bib119]). Seizures are considered to be initiated by M1 receptors and maintained by N-methyl-D-aspartate (NMDA) receptors (ionotropic glutamate receptors) ([@bib108]; [@bib135]). In vivo microdialysis studies have also shown increased hippocampal glutamate levels upon pilocarpine administration ([@bib135]). Seizures result in NMDA receptor activation and an increase in glutamate release from neurons, which accumulates in the brain interstitial fluid ([@bib59]). This contributes to the excitotoxic damage, loss of neurons, and resulting pathophysiology of SE ([@bib13]; [@bib47]). This increase in glutamatergic signalling increases Cycloogenase-2 (COX-2) levels ([@bib138]). The enzyme COX-2 plays an essential role in peroxidation of arachidonic acid and prostaglandin synthesis, which is responsible for inflammation ([@bib115]). Transcriptional upregulation of the COX-2 gene has been observed in both animal ([@bib156]; [@bib71]; [@bib139]; [@bib78]) and human cases of seizure ([@bib37]). Inhibition of COX-2 terminates NMDA receptor-mediated excitotoxic damage of neurons ([@bib91]; [@bib57]). Generation of COX products such as prostaglandin E2 can also be blocked by inhibiting the NMDA receptor ([@bib115]), thus suggesting a strong link between NMDA receptor activation and COX-2 expression. Both in vivo and in vitro rodent studies have revealed that glutamate increases PGP expression and transport activity in the brain ([@bib166]), both of which can be blocked using either MK-801, a non-competitive NMDA receptor antagonist, or indomethacin, a non-selective COX inhibitor ([@bib14]), as COX-2 has also been shown to increase PGP levels ([@bib113]). In addition to pilocarpine, several AEDs are also PGP substrates. Studies have shown that an increase in seizure activity causes an increase in expression of PGP, resulting in an increased rate of AED efflux at the BBB, which might explain why AEDs are ineffective in stopping SE onset ([@bib89]; [@bib76]). Studies on pharmacoresistant rats show lower PGP expression levels in the brain than those in AED-responsive rats ([@bib155]). Similar to its effect on pilocarpine uptake, application of tariquidar results in enhanced brain uptake of AEDs as well ([@bib19]; [@bib150]). It could be assumed that PGP has a protective role when activated against pilocarpine in animal models. However, this prolonged activation also occurs as a result of seizures. Thus, an initial protective mechanism becomes the cause of pharmacoresistance.

This effect is the reason why some studies report diazepam as having a positive effect, while others report that it fails to terminate SE ([@bib144]; [@bib70]; [@bib157]; [@bib67]; [@bib53]; [@bib109]; [@bib4]; [@bib165]). In addition to diazepam, several other drugs have also been tested against SE to reduce mortality rates in animal models; diazepam, phenobarbital, phenytoin, valproate, and carbamazepine have been shown to be ineffective in terminating SE in the LiCl-pilocarpine model ([@bib105]; [@bib15]; [@bib75]). The combination of diazepam with barbiturates such as pentobarbital is reported to be more useful in stopping SE ([@bib82]; [@bib45]; [@bib15]). NS-398, a COX-2 inhibitor, administered along with diazepam has also been shown to reduce SE severity ([@bib143]). A study showed that use of MK-801 combined with diazepam was able to terminate all manifestations of SE ([@bib158]). The use of MK-801 alone cannot completely stop seizure activity; however, unlike diazepam, it can block electroencephalogram (EEG) pattern changes that usually occur during SE ([@bib158]). Applying MK-801 alone also allows rats to survive SE; however, the recovery period is much longer than the time required when MK-801 is administered along with diazepam, thus suggesting that MK-801 potentiates the effects of diazepam ([@bib158]). Ketamine, an NMDA receptor antagonist, has also been shown to have a neuroprotective role post-SE ([@bib44]). An interesting modification of the LiCl-pilocarpine model is the protocol used by [@bib49], wherein LiCl is injected as per the original protocol; however, the pilocarpine dose to be given the following day is altered. Instead of a single dose of 30 mg/kg, the dose is divided into individual doses of 10 mg/kg that are administered at 30-minute intervals until SE onset. Compared with the original protocol, this revised protocol dramatically reduces the mortality rates by 50%. As animals differ in their tolerance to pilocarpine, this method ensures that animals are not unnecessarily given high doses and improves the induction probability. These results were also observed in several other studies using both pilocarpine and LiCl-pilocarpine models ([@bib20]; [@bib83]; [@bib111]; [@bib163]).

6. Rise of the pilocarpine model: an improved approach {#sec6}
======================================================

The most remarkable improvement made to the LiCl-pilocarpine model, however, is the Reduced Intensity Status Epilepticus (RISE) model ([@bib103]; [@bib110]). This model is an accumulation of several observations. Built on the same fundamentals as the previous protocol suggested by [@bib49], this study also divides the single pilocarpine dose into smaller doses that are administered at 30-minute intervals. However, upon animals scoring ≥ Stage 3 on the Racine scale, 2.5 mg/kg of xylazine is injected. One hour later, this is followed by administration of a 1 ml/kg drug cocktail consisting of MK-801 (0.1 mg/kg), diazepam (2.5 mg/kg), and 2-methyl-6-(phenylethynyl)pyridine (MPEP) (20 mg/kg). SE terminates within 30 min, with animals fully recovering within 12 h. The frequency of seizures is comparable to those observed with high doses of pilocarpine in previous studies. Animals demonstrate variability and clusters of seizures, which are also observed in human SE, further highlighting the translational significance of this model ([@bib43]; [@bib5]; [@bib8]). Consistent SRS also develop after a latency period. According to [@bib103], there is an absence of overall brain damage compared with other models, accompanied by alterations in the temporal network. The in vitro studies also revealed similar electrophysiological readings as observed in paediatric and adult patients. Features such as fast oscillatory activity and ictal-like events were also observed in in vivo as well as in vitro studies. Xylazine is an adrenergic alpha-receptor agonist that is a common muscle relaxant. Studies show that administration of a low dose of xylazine to animals with SE can minimise the intensity of clonic muscle contractions without changing electrographic seizures ([@bib164]; [@bib142]). This is important as locomotor hyperactivity and ataxia can cause fatigue in animals, thus increasing their mortality ([@bib103]). Although both convulsive and non-convulsive SE share the same EEG patterns, convulsive seizures are associated with a higher mortality rate ([@bib141]). With this reduction in convulsive SE, there is a reduced likelihood of secondary generalization in sub-cortical sites, especially the brainstem ([@bib126]). As stated previously, several studies have used NMDA antagonists, alone or combined with diazepam ([@bib158]; [@bib44]). However, the inspiration to use a combination of MPEP and an mGluR5 antagonist along with MK-801 and diazepam came from [@bib140]. This previous study used the same drug cocktail in a pilocarpine mouse model (300 mg/kg) and was able to terminate the seizures, simultaneously preventing early hippocampal cell death. The RISE model utilises the same drug cocktail with a small modification; the MPEP dose is reduced, and the diazepam dose is increased. Thus, it is able to reduce the mortality rate to 1% but still maintain high morbidity, replicating the epileptogenic characteristics observed in clinical cases of SE and making it a consistent, reproducible, and clinically translatable model for SE. This study on the RISE model was further followed up by another study investigating the underlying biochemical mechanisms involved in the initiation, development and establishment of this model ([@bib110]). Similar to human SE, the study observed alterations in several different receptor expression levels at various time points leading up to SE. These changes also varied depending on the brain regions, for example there were delayed receptor changes in the temporal lobe structures, suggesting that the epileptogenic activity continued long after the initial seizure ([@bib133]; [@bib134]; [@bib110]). This is beneficial to the model as absence of any ictal activity would make the creation of this model futile. All in all, this proves that the RISE model is reproducible and a good representative model for studying SE.

7. Conclusion {#sec7}
=============

The pilocarpine model of SE has undergone several modifications over the last few decades. From its initial single high dose of 400 mg/kg to its most recent improvement with the RISE model, all of these refinements were essential to ensure reduced mortality rates without compromising the SE induction probability. Even though the use of the original model resulted in higher mortality rates, its use was necessary because of the lack of sufficient clinically translatable models of SE at the time. The high-dose pilocarpine model was the first of its kind that satisfied all of the criteria essential for an animal model of SE: a latency period followed by SRS, replication of behavioural, electrographic, metabolic, and neuropathological changes, and pharmacoresistance to AEDs similar to that observed in human SE. Compared with other models, the original pilocarpine model was also more suitable for investigating the underlying mechanisms of SE and its resulting AED pharmacoresistance, thus for the first time giving researchers hope of designing potential therapeutics. The obvious drawbacks were the high mortality rates and limited SE induction in animals. These problems were soon mitigated with the introduction of the LiCl-pilocarpine model. This model was able to replicate all aspects of the pilocarpine model with the addition of lithium (24 h prior) and a much lower dose of pilocarpine. Although this alteration did improve the model to a certain extent, it did not completely curtail the problems. Several animals did not survive SE onset, and most AEDs were shown to be ineffective in stopping seizure activity. High mortality rates need to be considered because it is animal lives that are being dealt with. In animal studies, scientists must abide by the principles of the 3Rs: replacement, reduction, and refinement. To this end, several researchers have suggested modifications that could be made to the pilocarpine model. Of these, the novel protocol suggested by [@bib49] was of significant advantage. Dividing the single large dose of pilocarpine into several smaller doses to be administered at 30-minute intervals ensured lower mortality rates than the previous models. This new strategy was also able to generate a larger number of animals with induced SE. However, the most critical advancement was the introduction of the RISE model, which not only reduced the mortality rate (1%) but also increased SE induction and morbidity. This model, using a combination of previous research, presented a drug cocktail that was able to successfully stop seizures, thus also achieving two of principles of the 3Rs: reduction and refinement. With these improvements, animals are now able to survive longer, thus reigniting the hope for potential new therapeutics and effective drug targets for SE.
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